Literature DB >> 22262591

Design considerations in an active medical product safety monitoring system.

Joshua J Gagne1, Bruce Fireman, Patrick B Ryan, Malcolm Maclure, Tobias Gerhard, Sengwee Toh, Jeremy A Rassen, Jennifer C Nelson, Sebastian Schneeweiss.   

Abstract

Active medical product monitoring systems, such as the Sentinel System, will utilize electronic healthcare data captured during routine health care. Safety signals that arise from these data may be spurious because of chance or bias, particularly confounding bias, given the observational nature of the data. Applying appropriate monitoring designs can filter out many false-positive and false-negative associations from the outset. Designs can be classified by whether they produce estimates based on between-person or within-person comparisons. In deciding which approach is more suitable for a given monitoring scenario, stakeholders must consider the characteristics of the monitored product, characteristics of the health outcome of interest (HOI), and characteristics of the potential link between these. Specifically, three factors drive design decisions: (i) strength of within-person and between-person confounding; (ii) whether circumstances exist that may predispose to misclassification of exposure or misclassification of the timing of the HOI; and (iii) whether the exposure of interest is predominantly transient or sustained. Additional design considerations include whether to focus on new users, the availability of appropriate active comparators, the presence of an exposure time trend, and the measure of association of interest. When the key assumptions of self-controlled designs are fulfilled (i.e., lack of within-person, time-varying confounding; abrupt HOI onset; and transient exposure), within-person comparisons are preferred because they inherently avoid confounding by fixed factors. The cohort approach generally is preferred in other situations and particularly when timing of exposure or outcome is uncertain because cohort approaches are less vulnerable to biases resulting from misclassification.
Copyright © 2012 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2012        PMID: 22262591     DOI: 10.1002/pds.2316

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  20 in total

1.  Empirical performance of a new user cohort method: lessons for developing a risk identification and analysis system.

Authors:  Patrick B Ryan; Martijn J Schuemie; Susan Gruber; Ivan Zorych; David Madigan
Journal:  Drug Saf       Date:  2013-10       Impact factor: 5.606

Review 2.  Desideratum for evidence based epidemiology.

Authors:  J Marc Overhage; Patrick B Ryan; Martijn J Schuemie; Paul E Stang
Journal:  Drug Saf       Date:  2013-10       Impact factor: 5.606

3.  Moving along the yellow brick (card) road?

Authors:  Stephen J W Evans
Journal:  Drug Saf       Date:  2013-10       Impact factor: 5.606

4.  A comparison of the empirical performance of methods for a risk identification system.

Authors:  Patrick B Ryan; Paul E Stang; J Marc Overhage; Marc A Suchard; Abraham G Hartzema; William DuMouchel; Christian G Reich; Martijn J Schuemie; David Madigan
Journal:  Drug Saf       Date:  2013-10       Impact factor: 5.606

5.  Harnessing a health information exchange to identify surgical device adverse events for urogynecologic mesh.

Authors:  Jeanne Ballard; Marc Rosenman; Michael Weiner
Journal:  AMIA Annu Symp Proc       Date:  2012-11-03

6.  Active safety monitoring of new medical products using electronic healthcare data: selecting alerting rules.

Authors:  Joshua J Gagne; Jeremy A Rassen; Alexander M Walker; Robert J Glynn; Sebastian Schneeweiss
Journal:  Epidemiology       Date:  2012-03       Impact factor: 4.822

7.  Does design matter? Systematic evaluation of the impact of analytical choices on effect estimates in observational studies.

Authors:  David Madigan; Patrick B Ryan; Martijn Schuemie
Journal:  Ther Adv Drug Saf       Date:  2013-04

8.  Tobacco Smoking Is a Medical Problem. We Ought to Treat It Like One.

Authors:  Ravi Kalhan; John T Wilkins; Brian L Hitsman
Journal:  Am J Respir Crit Care Med       Date:  2018-04-01       Impact factor: 21.405

9.  A modular, prospective, semi-automated drug safety monitoring system for use in a distributed data environment.

Authors:  Joshua J Gagne; Shirley V Wang; Jeremy A Rassen; Sebastian Schneeweiss
Journal:  Pharmacoepidemiol Drug Saf       Date:  2014-04-30       Impact factor: 2.890

10.  Non-Vitamin K Antagonist Oral Anticoagulants and Angioedema: A Cohort and Case-Crossover Study.

Authors:  John G Connolly; Sebastian Schneeweiss; Robert J Glynn; Joshua J Gagne
Journal:  Drug Saf       Date:  2019-11       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.